文献速递免疫规划

NS1截短型猪用减毒活流感病毒疫苗对北美和欧洲主要H3N2谱系猪流感病毒感染的功效

Efficacy of the NS1-truncated live attenuated influenza virus vaccine for swine against infection with viruses of major North American and European H3N2 lineages.
PubMed 文献 · Vaccine · 2022-03-30

研究评估了NS1截短型H3N2猪用减毒活疫苗TX98 LAIV对欧洲和北美主要H3N2猪流感病毒谱系的交叉保护效果。结果显示TX98 LAIV可部分阻止北美IV簇H3N2的鼻腔排毒和肺部复制(2/4猪)、阻止北美新型人源样H3N2的明显鼻腔排毒(2/4猪),并将欧洲H3N2在下呼吸道的复制降至最低滴度(1/3猪)。尽管未检测到针对异源病毒的显著交叉反应抗体,部分交叉保护可能依赖细胞和黏膜免疫应答。

要点

  • TX98 LAIV对北美IV簇H3N2可阻止2/4猪的鼻腔排毒和肺部复制。
  • 对北美新型人源样H3N2可阻止2/4猪的明显鼻腔排毒。
  • 对欧洲H3N2可将1/3猪下呼吸道复制降至最低滴度。

核心结论

  • TX98 LAIV可对广泛的H3N2猪流感病毒提供部分保护,可能适合作为异源 prime-boost 免疫策略的初始疫苗。

研究设计与样本

  • 研究评估TX98 LAIV对代表欧洲和北美主要H3N2猪流感病毒谱系的异源流感病毒的交叉保护水平。

主要发现

  • TX98 LAIV阻止了北美IV簇H3N2猪流感病毒在2/4猪的鼻腔排毒和肺部复制。
  • TX98 LAIV阻止了北美新型人源样H3N2猪流感病毒在2/4猪的明显鼻腔排毒。
  • TX98 LAIV将欧洲H3N2猪流感病毒在下呼吸道的复制降至最低滴度(1/3猪)。
  • TX98 LAIV在血清中诱导了针对同源病毒的中和抗体,在鼻和肺中程度较低,但未检测到针对异源猪流感病毒的显著交叉反应抗体滴度。
  • 部分交叉保护可能依赖于针对猪流感病毒蛋白保守部分的细胞和黏膜免疫应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Control of swine influenza A virus (swIAV) in North America and Europe is complicated because multiple antigenically distinct swIAV strains co-circulate in the field, and no vaccine is available that can provide broad cross-protection against all these swIAVs. In 2017, the first live attenuated influenza vaccine (LAIV) for swine was licensed in the US. The non-structural protein 1 (NS1)-truncated cluster I H3N2 strain A/swine/Texas/4199-2/98 NS1del126 (TX98 LAIV) in this vaccine provides partial cross-protection against heterologous North American cluster II and IV H3N2 swIAV strains. Its efficacy against European or more recent North American H3N2 lineages remains to be investigated. In this study, we evaluated the level of cross-protection against heterologous IAVs representative of the major H3N2 swIAV lineages in Europe and North America. TX98 LAIV prevented both nasal shedding and replication in the lungs of a North American cluster IV H3N2 swIAV for 2/4 pigs, prevented considerable nasal shedding of a North American novel human-like H3N2 swIAV for 2/4 pigs, and reduced replication of a European H3N2 swIAV in the lower respiratory tract to minimal titers for 1/3 pigs. Although TX98 LAIV elicited neutralizing antibodies against the homologous virus in serum and to a lesser extent in nose and lungs, no significant cross-reactive antibody titers against the heterologous swIAVs were detected. Partial cross-protection therefore likely relies on cellular and mucosal immune responses against conserved parts of the swIAV proteins. Since TX98 LAIV can offer partial protection against a broad range of H3N2 swIAVs, it might be a suitable priming vaccine for use in a heterologous prime-boost vaccination strategy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vandoorn E, Parys A, Chepkwony S, et al. Efficacy of the NS1-truncated live attenuated influenza virus vaccine for swine against infection with viruses of major North American and European H3N2 lineages. Vaccine. 2022. PMID: 35367071. doi:10.1016/j.vaccine.2022.03.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。